share_log

SenesTech | 10-K/A: Annual report (Amendment)

SenesTech | 10-K/A: Annual report (Amendment)

SenesTech | 10-K/A:年度报表(修正版)
美股SEC公告 ·  04/29 16:10

Moomoo AI 已提取核心信息

SenesTech, a biotechnology company specializing in fertility control products for pests, filed an amended annual report for the fiscal year ended December 31, 2023. The report, filed with the SEC on February 21, 2024, was amended to include additional information required for the upcoming annual meeting of stockholders. The company's common stock is traded on the Nasdaq Capital Market under the symbol SNES. As of June 30, 2023, the market value of SenesTech's common stock held by non-affiliates was approximately $3.32 million, with 247,040 shares outstanding. By February 20, 2024, the number of outstanding shares had increased to 5,144,632. The report details the company's executive leadership, including the CEO Joel L. Fruendt, and the board of directors, highlighting their qualifications and contributions to the company's strategic...Show More
SenesTech, a biotechnology company specializing in fertility control products for pests, filed an amended annual report for the fiscal year ended December 31, 2023. The report, filed with the SEC on February 21, 2024, was amended to include additional information required for the upcoming annual meeting of stockholders. The company's common stock is traded on the Nasdaq Capital Market under the symbol SNES. As of June 30, 2023, the market value of SenesTech's common stock held by non-affiliates was approximately $3.32 million, with 247,040 shares outstanding. By February 20, 2024, the number of outstanding shares had increased to 5,144,632. The report details the company's executive leadership, including the CEO Joel L. Fruendt, and the board of directors, highlighting their qualifications and contributions to the company's strategic direction. The executive compensation section reveals that CEO Joel L. Fruendt received a total compensation of $343,044 in 2023, while EVP and CFO Thomas C. Chesterman received $261,431. The report also outlines the company's equity compensation plans, with 7,804,193 securities to be issued upon the exercise of outstanding options, warrants, and rights. SenesTech's board of directors has a majority of independent members, as required by Nasdaq listing standards. The company has adopted policies for the pre-approval of audit and non-audit services to ensure the independence of its auditors. The financial statements and schedules, along with a list of exhibits, are provided in the report, offering transparency into the company's financial and operational status.
专门生产害虫生育力控制产品的生物技术公司SenesTech提交了截至2023年12月31日的财年的修订年度报告。该报告于2024年2月21日向美国证券交易委员会提交,经过修订,纳入了即将举行的年度股东大会所需的更多信息。该公司的普通股在纳斯达克资本市场上交易,股票代码为SNES。截至2023年6月30日,非关联公司持有的SenesTech普通股的市值约为332万美元,已发行股票为247,040股。到2024年2月20日,已发行股票数量已增加到5,144,632股。该报告详细介绍了公司的行政领导层,包括首席执行官乔尔·弗鲁恩特和董事会,重点介绍了他们的资格和对公司战略方向的贡献。高管薪酬部分显示...展开全部
专门生产害虫生育力控制产品的生物技术公司SenesTech提交了截至2023年12月31日的财年的修订年度报告。该报告于2024年2月21日向美国证券交易委员会提交,经过修订,纳入了即将举行的年度股东大会所需的更多信息。该公司的普通股在纳斯达克资本市场上交易,股票代码为SNES。截至2023年6月30日,非关联公司持有的SenesTech普通股的市值约为332万美元,已发行股票为247,040股。到2024年2月20日,已发行股票数量已增加到5,144,632股。该报告详细介绍了公司的行政领导层,包括首席执行官乔尔·弗鲁恩特和董事会,重点介绍了他们的资格和对公司战略方向的贡献。高管薪酬部分显示,首席执行官乔尔·弗鲁恩特在2023年获得的总薪酬为343,044美元,而执行副总裁兼首席财务官托马斯·切斯特曼的总薪酬为261,431美元。该报告还概述了公司的股权补偿计划,在行使未偿还期权、认股权证和权利后,将发行7,804,193只证券。根据纳斯达克上市标准的要求,SenesTech的董事会由独立成员占多数。该公司已采取了审计和非审计服务的预先批准政策,以确保其审计师的独立性。报告中提供了财务报表和附表以及证物清单,使公司的财务和运营状况更加透明。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息